Elizabeth Fox

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor
    Elizabeth Fox
    National Cancer Institute, Pediatric Oncology Branch, Bethesda, MD 20892, USA
    Expert Rev Anticancer Ther 7:447-59. 2007
  2. ncbi request reprint Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey
    Elizabeth Fox
    Pharmacology and Experimental Therapeutics Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, 10 13C193, 10 Center Drive, MSC 1920, Bethesda, MD 20892, USA
    J Pharmacol Exp Ther 301:1003-11. 2002
  3. pmc Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas
    Elizabeth Fox
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 15:7361-7. 2009
  4. doi request reprint Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors
    Elizabeth Fox
    Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Bethesda, MD 20892 1101, USA
    Cancer Chemother Pharmacol 66:737-43. 2010
  5. ncbi request reprint A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors
    Elizabeth Fox
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 12:4882-7. 2006
  6. doi request reprint A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors
    Elizabeth Fox
    Authors Affiliations Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 14:1111-5. 2008
  7. ncbi request reprint Clinical trial design for target-based therapy
    Elizabeth Fox
    Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Oncologist 7:401-9. 2002
  8. doi request reprint Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates
    Shana Jacobs
    Pediatric Oncology Branch, NCI, National Institutes of Health, Bldg 10 CRC Rm 1 5750, 10 Center Drive, Bethesda, MD 20892, USA
    Cancer Chemother Pharmacol 65:817-24. 2010
  9. doi request reprint The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates
    Leigh Marcus
    National Cancer Institute, Pediatric Oncology Branch, 10 Center Drive, Building 10 CRC, Room 1 5742, Bethesda, MD 20892 1101, USA
    Cancer Chemother Pharmacol 69:247-52. 2012
  10. pmc Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group
    Brigitte C Widemann
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
    Pediatr Blood Cancer 56:226-33. 2011

Detail Information

Publications33

  1. ncbi request reprint Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor
    Elizabeth Fox
    National Cancer Institute, Pediatric Oncology Branch, Bethesda, MD 20892, USA
    Expert Rev Anticancer Ther 7:447-59. 2007
    ..Tariquidar can be considered an ideal agent for testing the role of P-glycoprotein inhibition in cancer...
  2. ncbi request reprint Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey
    Elizabeth Fox
    Pharmacology and Experimental Therapeutics Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, 10 13C193, 10 Center Drive, MSC 1920, Bethesda, MD 20892, USA
    J Pharmacol Exp Ther 301:1003-11. 2002
    ..Thus, zidovudine penetration in brain ECF and CSF in nonhuman primates is limited to a similar extent, presumably by active transport, as in other species...
  3. pmc Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas
    Elizabeth Fox
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 15:7361-7. 2009
    ..To compare the effectiveness, tolerance, and pharmacokinetics of a single dose of pegfilgrastim to daily filgrastim in children and young adults with sarcomas treated with dose-intensive combination chemotherapy...
  4. doi request reprint Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors
    Elizabeth Fox
    Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Bethesda, MD 20892 1101, USA
    Cancer Chemother Pharmacol 66:737-43. 2010
    ..To describe the pharmacokinetics of orally administered ABT-751 and its conjugated metabolites in children with neuroblastoma and other solid tumors and to relate pharmacokinetic parameters to toxicity and therapeutic outcomes...
  5. ncbi request reprint A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors
    Elizabeth Fox
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 12:4882-7. 2006
    ..To determine the toxicity profile, dose-limiting toxicities, and maximum tolerated dose of ABT-751 administered orally once daily for 7 days, repeated every 21 days...
  6. doi request reprint A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors
    Elizabeth Fox
    Authors Affiliations Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 14:1111-5. 2008
    ..To determine the toxicity profile, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) of ABT-751 administered orally once daily for 21 days, repeated every 28 days in a pediatric population...
  7. ncbi request reprint Clinical trial design for target-based therapy
    Elizabeth Fox
    Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Oncologist 7:401-9. 2002
    ....
  8. doi request reprint Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates
    Shana Jacobs
    Pediatric Oncology Branch, NCI, National Institutes of Health, Bldg 10 CRC Rm 1 5750, 10 Center Drive, Bethesda, MD 20892, USA
    Cancer Chemother Pharmacol 65:817-24. 2010
    ..Microdialysis is a minimally invasive in vivo method for sampling small molecules in the blood and tissue extracellular fluid (ECF). The purpose of this study was to estimate the penetration of platinum analogs into the brain ECF...
  9. doi request reprint The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates
    Leigh Marcus
    National Cancer Institute, Pediatric Oncology Branch, 10 Center Drive, Building 10 CRC, Room 1 5742, Bethesda, MD 20892 1101, USA
    Cancer Chemother Pharmacol 69:247-52. 2012
    ..7 and 2.6%, respectively). We evaluated the plasma and CSF pharmacokinetics (PK) of satraplatin after an intravenous (IV) dose in NHP...
  10. pmc Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group
    Brigitte C Widemann
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
    Pediatr Blood Cancer 56:226-33. 2011
    ..The objectives of this trial were to define the toxicity profile, dose, pharmacokinetics, and pharmacodynamics of the farnesyl transferase (FTase) inhibitor, tipifarnib, in children and adolescents with hematological malignancies...
  11. pmc A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report
    Brigitte C Widemann
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 18:6011-22. 2012
    ....
  12. doi request reprint Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas
    Aerang Kim
    Pediatric Oncology Branch, NCI, CCR, Bethesda, Maryland, USA
    Pediatr Blood Cancer 60:396-401. 2013
    ..Monitoring long-term toxicities such as effects on growth and obtaining additional pharmacokinetic data were of importance due to the young age and long duration of therapy seen in previous phase I trials in children with NF1...
  13. doi request reprint The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates
    Aerang Kim
    Pediatric Oncology Branch, Pharmacology and Experimental Therapeutics Section, National Cancer Institute, 10 Center Drive, Building 10 CRC, Bethesda, MD 20892, USA
    Invest New Drugs 30:524-8. 2012
    ..We evaluated the plasma and cerebrospinal fluid (CSF) pharmacokinetics (PK) of sorafenib after an intravenous (IV) dose in a non-human primate (NHP) model...
  14. doi request reprint Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors
    Holly J Meany
    Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Bldg 10 CRC Rm 1 5750, Bethesda, MD 20892, USA
    Cancer Chemother Pharmacol 65:137-42. 2009
    ..Temozolomide pharmacokinetics were evaluated in children receiving concurrent O(6)-benzylguanine (O(6)BG), which enhanced the hematological toxicity of temozolomide...
  15. doi request reprint Characteristics and outcome of pediatric patients enrolled in phase I oncology trials
    Aerang Kim
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, 10 Center Drive, Building 10 CRC, Room 1 3872, Bethesda, MD 20892, USA
    Oncologist 13:679-89. 2008
    ..To describe the characteristics of pediatric subjects who enroll in phase I trials, to determine the associations between pre-enrollment characteristics and the risk for toxicity, and to analyze response and survival outcomes...
  16. pmc Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome
    Brigitte C Widemann
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892 1101, USA
    J Clin Oncol 28:3979-86. 2010
    ..To assess the role of the recombinant bacterial enzyme, glucarpidase (carboxypeptidase-G(2)), leucovorin, and thymidine in the management and outcome of patients with high-dose methotrexate (HDMTX) -induced nephrotoxicity...
  17. doi request reprint Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma
    Elizabeth Fox
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 19:4239-48. 2013
    ..Vandetanib, a VEGF and EGF receptor inhibitor, blocks RET tyrosine kinase activity and is active in adults with hereditary MTC...
  18. pmc Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma
    Elizabeth Fox
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Blood 111:566-73. 2008
    ..15 mg/kg per day. The response rate in children with relapsed APL is similar to the response rate in adults. This trial was registered as #NCT00020111 at www.ClinicalTrials.gov...
  19. pmc Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors
    Brigitte C Widemann
    Pediatric and Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 27:550-6. 2009
    ....
  20. ncbi request reprint Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors
    Katherine E Warren
    National Cancer Institute Neuro Oncology Branch, Building 82, Room 219, 9030 Old Georgetown Rd, Bethesda, MD 20892 8200, USA
    J Clin Oncol 23:7646-53. 2005
    ....
  21. doi request reprint Plasma and CNS pharmacokinetics of O4-benzylfolic acid (O4BF) and metabolite in a non-human primate model
    Meredith K Chuk
    Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Building 10 Rm 1W 5750, Bethesda, MD 20892, USA
    Cancer Chemother Pharmacol 67:1291-7. 2011
    ..We studied plasma and cerebrospinal fluid (CSF) pharmacokinetics and CSF penetration of O(4)BF in a non-human primate model...
  22. ncbi request reprint Plasma and cerebrospinal fluid pharmacokinetics of intravenously administered ABT-751 in non-human primates
    Steve Y Cho
    Pediatric Oncology Branch, National Cancer Institute NCI, Bethesda, MD 20892, USA
    Cancer Chemother Pharmacol 60:563-7. 2007
    ..The plasma and cerebrospinal fluid (CSF) pharmacokinetics of ABT-751, after a short intravenous infusion, were evaluated in a non-human primate (Macaca mulatta) model that is highly predictive of the CSF penetration of drugs in humans...
  23. pmc Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas
    Brigitte C Widemann
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland B W, E D, A G, P W, S M, E F, F B Cancer Therapy Evaluation Program, Investigational Drug Branch, National Cancer Institute, Bethesda, Maryland J W Biostatistics and Data Management Section, National Cancer Institute, Bethesda, Maryland S S Diagnostic Radiology Department, National Institutes of Health, Bethesda, Maryland N P The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania J B, E F, F B Ann and Robert H Lurie Children s Hospital, Chicago, Illinois S G Department of Genetics, University of Alabama at Birmingham, South Birmingham, Alabama B K Expert Image Analysis LC, Potomac, Maryland J S Dana Farber Children s Hospital Cancer Center, Boston, Massachusetts M K Cincinnati Children s Hospital, Cincinnati, Ohio J P Children s National Medical Center, Washington, DC A K US Army Medical Research and Material Command, Fort Detrick, Maryland W S Children s Hospital of Alabama, Birmingham, Alabama A R
    Neuro Oncol 16:707-18. 2014
    ..The activity of tipifarnib, which blocks RAS signaling by inhibiting its farnesylation, was tested in children and young adults with NF1 and progressive PNs...
  24. pmc (111)In-octreotide scintigraphy for identification of metastatic medullary thyroid carcinoma in children and adolescents
    Maya Lodish
    Section on Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Clin Endocrinol Metab 97:E207-12. 2012
    ..Most medullary thyroid cancers (MTC) express somatostatin receptors; therefore, (111)In-octreotide somatostatin receptor scintigraphy (SRS) may be useful in detecting sites of metastases in children with MTC...
  25. ncbi request reprint Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates
    Shana S Jacobs
    Pharmacology and Experimental Therapeutics Section, Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Bethesda, MD 20815, USA
    Clin Cancer Res 11:1669-74. 2005
    ..Describe and compare the central nervous system pharmacology of the platinum analogues, cisplatin, carboplatin, and oxaliplatin and develop a pharmacokinetic model to distinguish the disposition of active drug from inert platinum species...
  26. pmc Automated volumetric growth plate measurement using magnetic resonance imaging for monitoring skeletal toxicity in children treated on investigational drug trials
    Aerang Kim
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 17:5982-90. 2011
    ..Careful evaluation of skeletal toxicity in the clinical development of targeted therapies for children is required. We validated a novel method to measure the growth plate volume using MRI...
  27. ncbi request reprint Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas
    Brigitte C Widemann
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 24:507-16. 2006
    ....
  28. ncbi request reprint Cytological identification of metastatic epithelial nephroblastoma in pleural fluid: report of a case and review of literature
    Malcolm Schinstine
    Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1500, USA
    Diagn Cytopathol 34:621-5. 2006
    ..Many cystic and tubular structures were identified. The tumor cells demonstrated strong CD56 and WT1 immunoreactivity. The histology of a subsequent surgical specimen reflected the features seen in cytology...
  29. ncbi request reprint Pancreatoblastoma metastases to the brain. Case illustration
    Nicholas J Szerlip
    Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Room 5D37, Bethesda, Maryland 20892 1414, USA
    J Neurosurg 106:169. 2007
  30. ncbi request reprint Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas
    Dusica Babovic-Vuksanovic
    Department of Medical Genetics, Mayo College of Medicine, Rochester, MN, USA
    Pediatr Neurol 36:293-300. 2007
    ..The second dose level was the pharmacokinetically comparable dose and is being used in an ongoing phase II trial of pirfenidone for children with neurofibromatosis 1 and progressive plexiform neurofibroma...
  31. ncbi request reprint The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates
    Holly J Meany
    Children s National Medical Center, Washington, DC, USA
    Cancer Chemother Pharmacol 62:387-92. 2008
    ..We evaluated the plasma and cerebrospinal fluid (CSF) pharmacokinetics of erlotinib and its active metabolite OSI-420 after an intravenous (IV) dose in a non-human primate model...
  32. ncbi request reprint Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis
    Ronald J Bernardi
    Texas Children s Hospital, Baylor College of Medicine, Houston, TX, 77030, USA
    Cancer Chemother Pharmacol 62:355-61. 2008
    ....
  33. pmc Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposium
    Ramsis K Benjamin
    Brain Tumor Center, Massachusetts General Hospital, Boston, MA 02114, USA
    Neuro Oncol 6:65-74. 2004
    ..In doing so we provide a rationale for the use of this technology by a National Cancer Institute consortium, New Approaches to Brain Tumor Therapy, to measure levels of drugs in brain tissue as part of phase 1 trials...